Tuesday July 17, 2012 0 commentsGREENWOOD VILLAGE - Ampio Pharmaceuticals Inc. (Nasdaq: AMPE) announced the advancement of NCE001 to preclinical development for the treatment of gliobastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition-of-matter-and-use patents in the U.S., Canada, Europe and China.
"NCE001 activates a specific intracellular phosphatase largely involved in inflammation, angiogenesis and cell proliferation pathways and has demonstrated remarkable in-vitro effects on aggressive cancer cells of these three lineages," said Dr. David Bar-Or, Ampio's chief science officer.
"We believe it may play an important role in treating these particularly aggressive cancers. Ampio has entered into a development agreement with Syngene International (Bangalore, India) to manufacture and conduct all preclinical stages of development of NCE001 all the way to an IND submission to the FDA."
Bar-Or said the three cancers do not currently have adequate treatment options and may qualify for an accelerated approval path by regulatory agencies, including the FDA.
An accelerated approval path could shave about four years off the time it takes to get final approval for the drug, Ampio said.